NASDAQ:RARX Ra Pharmaceuticals (RARX) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free RARX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$47.99▼$47.9950-Day Range$47.99▼$48.0052-Week Range$19.64▼$48.02Volume30,200 shsAverage Volume1.16 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Ra Pharmaceuticals alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Ra Pharmaceuticals Stock (NASDAQ:RARX)Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.Read More Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. RARX Stock News HeadlinesJanuary 23, 2024 | seekingalpha.comRA: Discount Continues To Leave Some OpportunitySeptember 8, 2023 | barrons.comImperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist InvestorsApril 24, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.May 29, 2023 | thestreet.comAnthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public OfferingJanuary 10, 2023 | msn.comUPDATE 1-AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealNovember 15, 2022 | 247wallst.comRA Capital Closes Position in Astria Therapeutics (ATXS)August 20, 2022 | investing.comRARX_old Historical DataJune 12, 2022 | msn.comPhilly-area pharma firm raises $118M for high blood pressure drugApril 24, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.June 8, 2022 | msn.comPhilly-area pharma firm raises $118M for high blood pressure drug for those who need extra helpMay 16, 2022 | finance.yahoo.comRa Medical Systems Reports First Quarter 2022 Financial ResultsSee More Headlines Receive RARX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2020Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RARX CUSIPN/A CIK1481512 Webwww.rapharma.com Phone617-401-4060FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.61% Return on Assets-41.60% Debt Debt-to-Equity Ratio0.01 Current Ratio14.78 Quick Ratio14.79 Sales & Book Value Annual Sales$3 million Price / Sales757.11 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book8.63Miscellaneous Outstanding Shares47,329,000Free FloatN/AMarket Cap$2.27 billion OptionableOptionable Beta1.05 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Douglas A. Treco (Age 61)Co-Founder, Pres, CEO & Director Mr. David C. Lubner (Age 55)Exec. VP & CFO Dr. Ramin Farzaneh-Far (Age 42)Chief Medical Officer Mr. Alonso RicardoChief Technology & Innovation Officer and Head of ResearchDr. Simon Read (Age 48)Chief Scientific Officer Key CompetitorsAimmune TherapeuticsNASDAQ:AIMTArvinasNASDAQ:ARVNTG TherapeuticsNASDAQ:TGTXDyne TherapeuticsNASDAQ:DYNVera TherapeuticsNASDAQ:VERAView All Competitors RARX Stock Analysis - Frequently Asked Questions How were Ra Pharmaceuticals' earnings last quarter? Ra Pharmaceuticals Inc (NASDAQ:RARX) released its quarterly earnings data on Thursday, February, 27th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.16. What other stocks do shareholders of Ra Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Novavax (NVAX), Viking Therapeutics (VKTX), Verastem (VSTM), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN), Galmed Pharmaceuticals (GLMD), Immunomedics (IMMU) and Rigel Pharmaceuticals (RIGL). When did Ra Pharmaceuticals IPO? Ra Pharmaceuticals (RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager. This page (NASDAQ:RARX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Goldtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ra Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.